GSK1292263

GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) [1].

Product Specifications

CAS Number

[1032823-75-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

GPR119

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/GSK1292263.html

Purity

99.71

Solubility

DMSO : ≥ 20 mg/mL

Smiles

CC(C1=NOC(N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(C)(=O)=O)=N1)C

Molecular Formula

C23H28N4O4S

Molecular Weight

456.56

Precautions

H302, H315, H320, H335

References & Citations

[1]X. Zhu, et al. GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment.|[2]Koji Matsumoto, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp Ther. 2018 Dec;367 (3) :509-517.